| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
2,252 |
1,838 |
$1.97M |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
458 |
385 |
$636K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
6,598 |
5,200 |
$348K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
3,614 |
3,224 |
$198K |
| 92235 |
|
2,506 |
2,237 |
$142K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,075 |
1,823 |
$117K |
| 92134 |
|
5,889 |
5,150 |
$106K |
| J9035 |
Injection, bevacizumab, 10 mg |
1,692 |
1,440 |
$87K |
| 92250 |
|
3,397 |
2,994 |
$70K |
| J7999 |
Compounded drug, not otherwise classified |
719 |
563 |
$25K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
616 |
549 |
$25K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
168 |
154 |
$14K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
449 |
379 |
$12K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
267 |
231 |
$10K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
15 |
12 |
$6K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
43 |
42 |
$4K |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
19 |
16 |
$0.00 |
| 1036F |
|
67 |
62 |
$0.00 |
| 4177F |
|
18 |
17 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
95 |
88 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
13 |
13 |
$0.00 |
| 4040F |
|
82 |
76 |
$0.00 |